The role of estrogen receptor β (ERβ) in malignant diseases-A new potential target for antiproliferative drugs in prevention and treatment of cancer

Margaret Warner; Jan Åke Gustafsson

doi:10.1016/j.bbrc.2010.02.144

The role of estrogen receptor β (ERβ) in malignant diseases-A new potential target for antiproliferative drugs in prevention and treatment of cancer

Margaret Warner, Jan Åke Gustafsson

Research output: Contribution to journal › Article › peer-review

72 Scopus citations

Abstract

The discovery of ERβ in the middle of the 1990s represents a paradigm shift in our understanding of estrogen signaling. It has turned out that estrogen action is not mediated by one receptor, ERα, but by two balancing factors, ERα and ERβ, which are often antagonistic to one another. Excitingly, ERβ has been shown to be widespread in the body and to be involved in a multitude of physiological and pathophysiological events. This has led to a strong interest of the pharmaceutical industry to target ERβ by drugs against various diseases. In this review, focus is on the role of ERβ in malignant diseases where the anti proliferative activity of ERβ gives hope of new therapeutic approaches.

Original language	English (US)
Pages (from-to)	63-66
Number of pages	4
Journal	Biochemical and Biophysical Research Communications
Volume	396
Issue number	1
DOIs	https://doi.org/10.1016/j.bbrc.2010.02.144
State	Published - May 21 2010

Keywords

Antiproliferative
Cancer
Drug
Gene expression
Nuclear receptor
Pharmaceutical
Transcription

ASJC Scopus subject areas

Biochemistry
Biophysics
Cell Biology
Molecular Biology

Access to Document

10.1016/j.bbrc.2010.02.144

Cite this

@article{5e0d205ea20f4ee585f05502aaab11b0,

title = "The role of estrogen receptor β (ERβ) in malignant diseases-A new potential target for antiproliferative drugs in prevention and treatment of cancer",

abstract = "The discovery of ERβ in the middle of the 1990s represents a paradigm shift in our understanding of estrogen signaling. It has turned out that estrogen action is not mediated by one receptor, ERα, but by two balancing factors, ERα and ERβ, which are often antagonistic to one another. Excitingly, ERβ has been shown to be widespread in the body and to be involved in a multitude of physiological and pathophysiological events. This has led to a strong interest of the pharmaceutical industry to target ERβ by drugs against various diseases. In this review, focus is on the role of ERβ in malignant diseases where the anti proliferative activity of ERβ gives hope of new therapeutic approaches.",

keywords = "Antiproliferative, Cancer, Drug, Gene expression, Nuclear receptor, Pharmaceutical, Transcription",

author = "Margaret Warner and Gustafsson, {Jan {\AA}ke}",

year = "2010",

month = may,

day = "21",

doi = "10.1016/j.bbrc.2010.02.144",

language = "English (US)",

volume = "396",

pages = "63--66",

journal = "Biochemical and Biophysical Research Communications",

issn = "0006-291X",

publisher = "Elsevier B.V.",

number = "1",

}

TY - JOUR

T1 - The role of estrogen receptor β (ERβ) in malignant diseases-A new potential target for antiproliferative drugs in prevention and treatment of cancer

AU - Warner, Margaret

AU - Gustafsson, Jan Åke

PY - 2010/5/21

Y1 - 2010/5/21

N2 - The discovery of ERβ in the middle of the 1990s represents a paradigm shift in our understanding of estrogen signaling. It has turned out that estrogen action is not mediated by one receptor, ERα, but by two balancing factors, ERα and ERβ, which are often antagonistic to one another. Excitingly, ERβ has been shown to be widespread in the body and to be involved in a multitude of physiological and pathophysiological events. This has led to a strong interest of the pharmaceutical industry to target ERβ by drugs against various diseases. In this review, focus is on the role of ERβ in malignant diseases where the anti proliferative activity of ERβ gives hope of new therapeutic approaches.

AB - The discovery of ERβ in the middle of the 1990s represents a paradigm shift in our understanding of estrogen signaling. It has turned out that estrogen action is not mediated by one receptor, ERα, but by two balancing factors, ERα and ERβ, which are often antagonistic to one another. Excitingly, ERβ has been shown to be widespread in the body and to be involved in a multitude of physiological and pathophysiological events. This has led to a strong interest of the pharmaceutical industry to target ERβ by drugs against various diseases. In this review, focus is on the role of ERβ in malignant diseases where the anti proliferative activity of ERβ gives hope of new therapeutic approaches.

KW - Antiproliferative

KW - Cancer

KW - Drug

KW - Gene expression

KW - Nuclear receptor

KW - Pharmaceutical

KW - Transcription

UR - http://www.scopus.com/inward/record.url?scp=77952302285&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952302285&partnerID=8YFLogxK

U2 - 10.1016/j.bbrc.2010.02.144

DO - 10.1016/j.bbrc.2010.02.144

M3 - Article

C2 - 20494112

AN - SCOPUS:77952302285

SN - 0006-291X

VL - 396

SP - 63

EP - 66

JO - Biochemical and Biophysical Research Communications

JF - Biochemical and Biophysical Research Communications

IS - 1

ER -

The role of estrogen receptor β (ERβ) in malignant diseases-A new potential target for antiproliferative drugs in prevention and treatment of cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this